

China

Hongbaiyi

COA, HPLC MR

0.1mg/vial, 10vials/box LR3-Insulin Like Growth Factor 1 (IGF-1) 9117.6

Basic Information

- Place of Origin:
- Brand Name:
- Certification:
- Model Number:
- Minimum Order Quantity: 5
- Packaging Details:
- Delivery Time:
- Payment Terms:
- Supply Ability:
- HBY-IGF1-Lr3
 5 boxes
 0.1mg/vial, 10vials/box
 3-5 work days after your payment
 MoneyGram, Western Union, T/T
 20.000 boxes /month
- IGF1-Lr3

Product Specification

- Name:
- CAS:
- Molecular Weight:
- Molecular Formula:
- Other Names:
- Specification:
- Physical Form:
- Purity:

IGF1-Lr3 0.1mg 946870-92-4 9117.6 C400H625N111O115S9 Long R3-IGF-1; IGF-1 Long R3 0.1mg/vial, 10vials/box Lyophilized Powder

99%





More Images





for more products please visit us on peptide-powder.com

0.1mg/vial, 10vials/box LR3-Insulin-Like Growth Factor 1 (IGF-1) 9117.6



Basic Information of 0.1mg Lean Muscle Mass Insulin-Like Growth Factor 1 Long R3 (IGF-1 LR3)

Product Name	IGF1- Lr3 0.1mg
Cas No.	946870-92-4
Molecular Formula	C400H625N111O115S9
Molecular Weight	9117.6
Appearance	White powder
Peptide Purity	99%
Shelf Life	2 years
Storage	2-8°C

What is 0.1mg Lean Muscle Mass Insulin-Like Growth Factor 1 Long R3 (IGF-1 LR3)

IGF-1 LR3 (insulin-like growth factor-1 long arginine 3) is a synthetic, modified construct of insulin-like growth factor-1. Because IGF-1 LR3 does not bind to IGF-1 binding proteins very well, it remains active up to 120 times longer than standard IGF-1. IGF-1 LR3 enhances cell division and growth boosts fat metabolism and increases muscle repair and hypertrophy by inhibiting myostatin. IGF-1 LR3 promotes tissue repair and maintenance throughout the body, making it a protective molecule against cell damage and the effects of aging.

The recommended dosage for men of IGF-1 LR3 is 40 - 50 mcg each day and 20 mcg/day for women. All dosing is a subcutaneous or intramuscular injection. You should take your dosage once or twice per day, preferably just before training or after your workout. On non-training days, doses should be with a meal in the morning. IGF-1 LR3 is dosed for 30 days and requires 2 weeks off before starting another cycle. You can expect some of the following with IGF-1LR3;

Regulates cellular DNA

Helps reverse aging

Reduces fat storage in the body

Increases pure muscle weight

Improves athletic performance Boosts muscle protein synthesis

Speeds up metabolism

Speeds up metabolism

Benefits of 0.1mg/vial, 10vials/box LR3-Insulin Like Growth Factor 1 (IGF-1) 9117.6

In general, IGF-1 LR3 can promote the following positive effects:

IGF-1 LR3 increases levels of growth hormone, which is essential for bone development during childhood and throughout adulthood

IGF-1 LR3 increases lean muscle mass

IGF-1 LR3 improves athletic performance

IGF-1 LR3 increased double curves in muscle cells leading to fuller muscle tissue

IGF-1 LR3 improved muscle recovery and reduced recovery time

IGF-1 LR3 reduces body fat

IGF-1 LR3 increased metabolism

IGF-1 LR3 regulates fat storage and encourages fat to go to bed for energy production

IGF-1 LR3 promotes protein synthesis in the body

IGF-1 LR3 improves antioxidant benefits and ligament strength

Fat Metabolism and Diabetes for LR3-Insulin Like Growth Factor 1 (IGF-1)

GF1-LR3 boosts fat metabolism in an indirect manner by binding to both the IGF-1R receptor and the insulin receptor. These actions increase glucose uptake from the blood by muscle, nerve, and Oliver cells. This results in an overall decrease in blood sugar levels, which then triggers adipose tissue as well as the liver to begin breaking down glycogen and triglycerides. Overall, this produces a net decrease in adipose tissue and net energy consumption (i.e. net catabolism)Given its role in reducing blood sugar levels, it should come as no surprise that IGF1-LR3 reduces insulin levels as well as the need for exogenous insulin in diabetes. In most cases, this translates into a 10% decrease in insulin requirements to maintain the same blood sugar levels, This fact may help scientists understand how to decrease insulin doses in individuals who have decreased

